Opportunity Information: Apply for RFA NR 12 003
Apply for RFA NR 12 003
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Application of Genomic Advances to Wound Repair (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.361 Nursing Research.
- This funding opportunity was created on Nov 18, 2011 and posted on Nov 18, 2011.
- Applicants must submit their applications by Jan 23, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Public housing authorities/Indian housing authorities City or township governments County governments Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Native American tribal governments (Federally recognized) Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses State governments Native American tribal organizations (other than Federally recognized tribal governments) Special district governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH National Institute of Nursing Research (NINR) grant opportunity titled "Application of Genomic Advances to Wound Repair (R21)" (Funding Opportunity Number RFA-NR-12-003) was designed to jump-start exploratory, early-stage research that connects modern genomics with the stubborn clinical problem of chronic wounds. In this announcement, NINR defines chronic wounds as wounds that have not moved through a normal reparative process within three months, and it focuses attention on both the biological reasons those wounds fail to heal and on the practical development of interventions that could prevent chronicity or speed healing once a wound has stalled.
The core goal is twofold. First, NINR is looking for studies that increase understanding of the genomic mechanisms involved in the development of chronic wounds and in wound repair. That includes research aimed at figuring out which genes, gene expression patterns, regulatory pathways, or other genomic factors are linked to delayed healing, persistent inflammation, infection susceptibility, impaired angiogenesis, or poor tissue regeneration. Second, the opportunity explicitly supports the development and testing of genomics-based interventions. In other words, the institute is not only interested in mapping out molecular signatures, but also in translating those signatures into approaches that can be used to prevent chronic wounds from forming or to help them close faster once they occur.
A major theme running through the announcement is risk identification and personalization. NINR anticipates that supported projects will expand the knowledge base needed to identify which individuals are at highest risk for developing chronic wounds, based on genomic profile and related biological markers. The longer-term vision is that these insights could help drive customized therapeutics and tailored interventions, meaning strategies matched to an individual’s genomic characteristics rather than relying on one-size-fits-all wound care. This aligns with broader precision medicine goals, but in this case applied specifically to wound development and healing trajectories.
Mechanistically, the opportunity centers on "genomic advances," which commonly encompasses areas like genetic variation, gene regulation, transcriptomics, epigenetics, and other genome-informed approaches that can clarify why healing succeeds in some people and fails in others. The emphasis on both "development and repair" signals that proposals could reasonably address upstream vulnerability (why a patient is prone to chronic wounds) as well as downstream biology (what blocks repair once tissue breakdown happens). The R21 mechanism also signals that NINR is encouraging innovative, potentially high-impact ideas that may still be in proof-of-concept stages, rather than requiring large-scale definitive trials at the outset.
From an administrative and funding standpoint, this was a discretionary grant opportunity using the NIH R21 funding mechanism, which typically supports exploratory and developmental research. The estimated total funding associated with the announcement was $2,000,000, with an award ceiling of $200,000. There was no cost sharing or matching requirement. The announcement was posted and created on November 18, 2011, with an original and current closing date of January 23, 2012, and it was archived on February 23, 2012. The CFDA listing associated with the program was 93.361 (Nursing Research), placing it squarely within the federal nursing research portfolio even though it draws heavily on genomics and translational biology.
Eligibility was broad across U.S.-based organizations and included public and private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), small businesses, for-profit organizations (other than small businesses), and multiple levels of government such as city/township, county, state, special district governments, public housing authorities, and independent school districts. The eligibility language also explicitly included a range of mission-focused and underserved-serving institutions and organizations, such as Historically Black Colleges and Universities (HBCUs), Hispanic Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations, along with certain regional organizations and eligible federal agencies. At the same time, the announcement made clear that non-U.S. entities were not eligible to apply, non-U.S. components of U.S. organizations were not eligible, and foreign components were not allowed under NIH policy as referenced in the NIH Grants Policy Statement.
Overall, this opportunity can be summarized as a targeted NIH initiative to move chronic wound research beyond descriptive clinical factors and into genome-informed explanations and interventions. By supporting studies that both uncover genomic mechanisms and test genomics-based approaches to prevention or faster healing, NINR aimed to lay groundwork for better risk stratification and more individualized wound care, with the practical end goal of reducing the burden of chronic wounds through more precise, biologically grounded strategies.
Frequently Asked Questions (FAQs)
What is the title of this NIH/NINR funding opportunity?
The funding opportunity is titled "Application of Genomic Advances to Wound Repair (R21)".
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA-NR-12-003.
Which NIH institute is sponsoring this opportunity?
This opportunity is sponsored by the NIH National Institute of Nursing Research (NINR).
What is the purpose of this grant opportunity?
The purpose is to jump-start exploratory, early-stage research that connects modern genomics with the clinical problem of chronic wounds. NINR is seeking projects that (1) improve understanding of genomic mechanisms involved in chronic wound development and wound repair, and (2) support development and testing of genomics-based interventions to prevent chronicity or speed healing.
How does NINR define a chronic wound for this announcement?
In this announcement, chronic wounds are defined as wounds that have not moved through a normal reparative process within three months.
What research areas are encouraged under this RFA?
The RFA emphasizes research that increases understanding of genomic mechanisms involved in chronic wound development and wound repair. This includes identifying genes, gene expression patterns, regulatory pathways, or other genomic factors associated with delayed healing and related biological problems.
Does this opportunity support intervention development, or only basic discovery work?
It supports both. In addition to mapping genomic mechanisms and molecular signatures, the opportunity explicitly supports the development and testing of genomics-based interventions aimed at preventing chronic wounds or helping wounds close faster once healing has stalled.
What kinds of wound-healing problems does NINR highlight as targets for genomic study?
The announcement calls attention to genomic factors linked to issues such as delayed healing, persistent inflammation, infection susceptibility, impaired angiogenesis, and poor tissue regeneration.
Is personalized or precision-medicine-focused work a priority here?
Yes. A major theme is risk identification and personalization. NINR anticipates projects will expand knowledge needed to identify individuals at high risk for chronic wounds based on genomic profiles and related biological markers, supporting a longer-term vision of customized therapeutics and tailored interventions.
What is meant by "genomic advances" in this opportunity?
Within the context provided, "genomic advances" commonly encompass areas such as genetic variation, gene regulation, transcriptomics, epigenetics, and other genome-informed approaches that can explain why healing succeeds in some people and fails in others.
Can proposals focus on why patients are prone to chronic wounds as well as what blocks repair after a wound occurs?
Yes. The announcement highlights both "development and repair," signaling that proposals may address upstream vulnerability (why an individual is prone to chronic wounds) and downstream biology (what blocks repair after tissue breakdown).
What grant mechanism is used for this opportunity?
This opportunity uses the NIH R21 mechanism, which typically supports exploratory and developmental research.
What does the R21 mechanism imply about the types of projects NINR is seeking?
Based on the description provided, the R21 mechanism signals an interest in innovative, potentially high-impact ideas that may be in proof-of-concept stages rather than requiring large-scale definitive trials at the outset.
What was the estimated total funding associated with this announcement?
The estimated total funding associated with the announcement was $2,000,000.
What was the award ceiling for this opportunity?
The award ceiling was $200,000.
Is cost sharing or matching required?
No. The announcement states there was no cost sharing or matching requirement.
When was the opportunity posted?
The announcement was posted (and created) on November 18, 2011.
What was the application closing date?
The original and current closing date listed was January 23, 2012.
Is this funding opportunity still open?
No. The announcement was archived on February 23, 2012, and the closing date was January 23, 2012.
What is the CFDA number associated with this program?
The CFDA listing associated with the program was 93.361 (Nursing Research).
What types of organizations were eligible to apply?
Eligibility was broad across U.S.-based organizations and included: public and private institutions of higher education; nonprofits (including 501(c)(3) and certain non-501(c)(3) entities); small businesses; for-profit organizations (other than small businesses); and multiple levels of government (city/township, county, state, special district governments, public housing authorities, and independent school districts).
Were mission-focused or underserved-serving institutions explicitly included?
Yes. The eligibility language explicitly included organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations, along with certain regional organizations and eligible federal agencies.
Are non-U.S. (foreign) organizations eligible to apply?
No. The announcement states that non-U.S. entities are not eligible to apply.
Can a U.S. organization include a non-U.S. component or foreign component in the project?
No. The announcement specifies that non-U.S. components of U.S. organizations are not eligible, and foreign components are not allowed under NIH policy as referenced in the NIH Grants Policy Statement.
How would you summarize the overall intent of this initiative?
Overall, this initiative aims to move chronic wound research beyond descriptive clinical factors toward genome-informed explanations and practical interventions, building groundwork for better risk stratification and more individualized wound care with the long-term goal of reducing the burden of chronic wounds.
Browse more opportunities from the same category: Education Health
Next opportunity: Application of Genomic Advances to Wound Repair (R01)
Previous opportunity: Lasker Clinical Research Scholars Program (Si2)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA NR 12 003
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA NR 12 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| Application of Genomic Advances to Wound Repair (R01) Apply for RFA NR 12 002 Funding Number: RFA NR 12 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care (R01) Apply for PA 12 024 Funding Number: PA 12 024 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Small Grants Program for Cancer Epidemiology (R03) Apply for PAR 12 039 Funding Number: PAR 12 039 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Research to Advance Vaccine Safety (R01) Apply for PA 12 037 Funding Number: PA 12 037 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research to Advance Vaccine Safety (R21) Apply for PA 12 038 Funding Number: PA 12 038 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| International Research Collaboration on Drug Abuse and Addiction Research (R01) Apply for PA 12 040 Funding Number: PA 12 040 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| International Research Collaboration on Drug Abuse and Addiction Research (R21) Apply for PA 12 041 Funding Number: PA 12 041 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| International Research Collaboration on Drug Abuse and Addiction Research (R03) Apply for PA 12 042 Funding Number: PA 12 042 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Limited Competition Competitive Revision for Technology Development within Biomedical Technology Research Centers (P41) Apply for PAR 12 046 Funding Number: PAR 12 046 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Cancer Education Grants Program (R25) Apply for PAR 12 049 Funding Number: PAR 12 049 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Palliative Care and End of Life in People Living with HIV/AIDS(R01) Apply for RFA NR 12 004 Funding Number: RFA NR 12 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Palliative Care and End of Life in People Living with HIV/AIDS (R21) Apply for RFA NR 12 005 Funding Number: RFA NR 12 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Limited Competition Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54) Apply for PAR 12 055 Funding Number: PAR 12 055 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition The Medical Education Partnership Initiative Linked Awards (MEPI) (R25) Apply for RFA TW 11 004 Funding Number: RFA TW 11 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| The Chernobyl Tissue Bank Coordinating Center (Limited Competition U24) Apply for RFA CA 12 501 Funding Number: RFA CA 12 501 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| NCI Mentored Research Scientist Development Award to Promote Diversity (K01) Apply for PAR 12 050 Funding Number: PAR 12 050 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08) Apply for PAR 12 051 Funding Number: PAR 12 051 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Mentored Patient Oriented Research Career Development Award to Promote Diversity (K23) Apply for PAR 12 052 Funding Number: PAR 12 052 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Maternal Nutrition and Pre pregnancy Obesity Effects on Mothers, Infants and Children (R01) Apply for PA 12 061 Funding Number: PA 12 061 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The NCI Transition Career Development Award to Promote Diversity (K22) Apply for PAR 12 062 Funding Number: PAR 12 062 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants

Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA NR 12 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
